The Centers for Medicare & Medicaid Services granted Medicare coverage for Personalis’ NeXT Personal minimal residual disease (MRD) assay for stage II and III breast cancer recurrence monitoring. The decision covers up to six years of surveillance and reflects growing payer acceptance of tumor‑informed sequencing for disease monitoring. Separately, Baylor Genetics won a multi‑year VA contract to provide pharmacogenomic (PGx) and hereditary cancer testing across the Veterans Affairs health system. Baylor installed a high‑throughput sequencing platform to support the program and emphasized capacity‑building and standardized pricing to improve access for veterans. Both moves expand clinical deployment of genomic diagnostics: one through coverage policy, the other via government contracting—signaling broader institutional adoption that could shape trial designs, reimbursement pathways, and lab service demand.